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Abstract
Rationale The loudness dependence of the auditory evoked
potential (LDAEP) is considered a noninvasive in vivo
marker of central serotonergic functioning in humans.
Nevertheless, results of genetic association studies point
towards a modulation of this biomarker by dopaminergic
neurotransmission.
Objective We examined the effect of dopaminergic modu-
lation on the LDAEP using L-3,4-dihydroxyphenylalanine
(levodopa)/benserazide (Madopar®) as a challenge agent in
healthy volunteers.
Methods A double-blind placebo-controlled challenge
design was chosen. Forty-two healthy participants
(21 females and 21 males) underwent two LDAEP
measurements, following a baseline LDAEP measurement
either placebo or levodopa (levodopa 200 mg/benserazide
50 mg) were given orally. Changes in the amplitude and
dipole source activity of the N1/P2 intensities (60, 70, 80,
90, and 100 dB) were analyzed.
Results The participants of neither the levodopa nor the
placebo group showed any significant LDAEP alterations
compared to the baseline measurement. The test–retest
reliability (Cronbachs Alpha) between baseline and inter-
vention was 0.966 in the verum group and 0.759 in the
placebo group, respectively.
Conclusions The administration of levodopa showed no
effect on the LDAEP. These findings are in line with other
trials using dopamine receptor agonists.
Keywords Dopamine . Loudness dependence auditory
evoked potentials (LDAEP) . Levodopa . Primary auditory
cortex . Serotonin
Introduction
Reliable methods for the in vivo assessment of the central
serotonergic system would be of great interest for the
understanding of neuropsychiatric disorders and for monitor-
ing the therapeutic efficacy of pharmacological treatments
(Hegerl and Juckel 2000). Parameters regarding peripheral
serotonin (5-HT) metabolism such as the concentration of
5-hydroxyindolacid in cerebrospinal fluid or the 5-HT
transporter (SERT) availability in thrombocytes do not
properly reflect central 5-HT functioning. They merely state
inconsistent snapshots. In contrast to this, the loudness
dependence of auditory evoked potentials (LDAEP) has
been reported to be a measure of central 5-HT activity in
humans (Hegerl et al. 2001; Hegerl and Juckel 1993, 1994;
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Juckel et al. 1997; Kawohl et al. 2008b; O'Neill et al. 2008a).
A pronounced LDAEP supposedly reflects a low central
5-HT neurotransmission and vice versa.
Nevertheless, the issue of specificity of the LDAEP for
the 5-HT system has been the topic of debate. Several
findings cast some doubt over its sensitivity to changes in
5-HT functioning alone (Juckel et al. 2008b, 1997; O'Neill
et al. 2006; Pogarell et al. 2004; Uhl et al. 2006). An
association between 5-HT (SERT) and dopamine (DAT)
transporter availability and the interindividual LDAEP has
been found in a [123I]beta-CIT single-photon emission
computed tomography (SPECT) study (Pogarell et al.
2004). High availability of the transporter enzymes,
indirectly suggesting reduced 5-HT and dopamine in the
synaptic cleft, was correlated with an increased LDAEP in
patients with obsessive–compulsive disorder. Dopaminergic
influence onto the LDAEP was stated. Lee at al. (Lee et al.
2010) found the LDAEP to be positively associated with
DAT in a trial with 49 healthy volunteers using SPECT to
approximate the availability of dopamine transporters and
serotonin transporters. After adjusting for age and gender,
the LDAEP was negatively associated with SERT. Further
evidence for the possible involvement of dopamine in the
genesis of LDAEP was stated.
A recent genetic association study has revealed an
association between single nucleotide polymorphisms
(SNPs) in the gene coding for the dopamine degrading
enzyme catechol-O-methyltransferase (COMT) and the
LDAEP (Juckel et al. 2008b). COMT is involved in the
inactivation of synaptic dopamine (Axelrod and Tomchick
1958). Functional SNPs in the COMT gene result in
attenuated dopamine catabolism, and several findings point
to a modification of the risk for psychotic disorders by
these genetic variants (Funke et al. 2005; Meyer-
Lindenberg and Weinberger 2006; Nicodemus et al.
2007). Another genetic association study revealed an
association between the functional SNPs in genes
coding for nitric oxide synthase (NOS): single nucleo-
tide polymorphisms in both NOS1- (G-84A_exon 1c
promoter polymorphism) and NOS3 gene (Glu298Asp) are
associated with a lower LDAEP. NOS is an enzyme
catalyzing the production of nitric oxyde (NO) from L-
arginine. NO is a gaseous molecule with neurotransmitter
properties that also interacts with dopaminergic transmis-
sion (Kawohl et al. 2008a).
The aforementioned studies point to a dopaminergic
influence on the LDAEP. However, O'Neill et al. (O'Neill et
al. 2006) could not find a significant effect on the LDAEP
after dopaminergic stimulation of the D1/D2/D3 receptors
with pergolide and D2/D3 receptors with bromocriptine. In
another trial of the same study group, selective serotonin and
dopamine depletion with greater than 80% plasma precursor
depletion had no effect on the LDAEP (O'Neill et al. 2008b).
Despite of O'Neill et al.’s findings we developed a
dopaminergic challenge with a naturalistic agent. Synthetic
dopamine receptor agonists, as used in the aforementioned
studies, exhibit different receptor affinities compared to
dopamine. In contrast, we decided to use the prodrug
levodopa due to its more naturalistic action via synaptic
dopamine; levodopa is the precursor of dopamine. It is
decarboxylized to dopamine, which cannot pass the blood–
brain barrier. Compared to synthetic agonists, levodopa
bares a decisive advantage in inducing dopaminergic
stimulation; after decarboxylation, levodopa acts as a
transmitter itself, thus modulating the dopaminergic effect
in the most naturalistic manner. In contrast to a synthetic
agonist, such as, bromocriptine, specific receptor affinities
do not have to be taken into account. Several trials have
shown an increase of synaptic dopamine level due to oral
intake of levodopa and benserazide (de la Fuente-Fernandez
et al. 2004; Floel et al. 2005; Khor and Hsu 2007;
Kumakura et al. 2004). In addition, we wanted to compute
the EEG data with the dipole source model to differentiate
between the primary and secondary auditory area. The
primary auditory area is considered to be the generator of
the LDAEP signal (Hegerl and Juckel 1993, 1994; Hegerl
1994; Hegerl et al. 1994). Hence, the aim of this study was
to investigate the influence of acute dopaminergic stimula-
tion on the LDAEP in healthy individuals with a challenge
agent not used so far. We hypothesized that the acute
synaptic dopamine excess caused by levodopa intake leads
to an intraindividual decrease of the LDAEP.
Methods
Participants
Healthy volunteers were selected among the staff and with
the help of the volunteer server of the Psychological
Institute of the University of Zürich. Normal hearing was
tested clinically.
The 42 healthy participants had not been treated for
any psychiatric disease in their lifetime and had no first-
degree relatives with psychiatric disorders. All partic-
ipants were drug free (except oral contraceptives) and
were asked to abstain from alcohol the day prior to the
session. Caffeine and nicotine intake were permitted to
avoid withdrawal symptoms. Four female and six male
participants were cigarette smokers. The volunteers were
examined for existing contraindications against the
intake of levodopa 200 mg/benserazide 50 mg and
domperidone 20 mg by standard blood tests and
electrocardiography. Psychiatric and somatic illnesses
were excluded by psychiatric and physical examination
by a physician trained in somatic and psychiatric
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medicine. A pregnancy test was carried out in female
volunteers before participating in the trial.
Forty-two healthy subjects (21 females, 21 males; mean
age placebo group, 34 years; mean age verum group,
33 years; SD 9.9; 7.8 respectively) attended in this trial.
Ethical issues
The study was carried out in compliance with the Declaration
of Helsinki and was approved by the ethics committee of the
Canton of Zurich including the specialized sub-commission
for neuroscience. All subjects gave written informed consent
and were paid customary expenses.
Study design and procedure
The study used a randomized double-blind placebo-
controlled challenge design. Each subject underwent
LDAEP measurement under two different conditions: (1)
baseline and (2) placebo or levodopa/ benserazide. The
levodopa/benserazide dosages were selected according to
the literature. Significant behavioral drug effects occur
under 200 mg levodopa and 50 mg benserazide (Black and
Mink 2000; Floel et al. 2005; Micallef-Roll et al. 2001).
After 8 h of fasting (Black and Mink 2000) in order to
exclude proteinous inhibition of the enteral levodopa
absorption, the participants arrived on the testing days at
8 o’clock in the morning and ate a low protein breakfast
(bread with butter and jam, orange juice). In order to reduce
the likelihood of any nausea following levodopa/benser-
azide intake, domperidone 20 mg was given orally (O'Neill
et al. 2006). Domperidone does not cross the blood/brain
barrier and acts as a peripheral dopamine antagonist
(O'Neill et al. 2006). Afterwards, a baseline LDAEP-
recording was performed. After this recording, levodopa/
benserazide in a dosage of 200 mg/50 mg or placebo were
applied orally. Both levodopa and placebo were given in
cachets that were not distinguishable, neither by the staff
nor the participants. The cachets had been labeled, listed,
and stored by a person independent to the trial staff. The
number of the cachet given to the volunteer was listed. At
the estimated tmax of levodopa (Floel et al. 2005) of 60 min
after oral intake the second measurement was conducted.
Blood pressure and pulse were measured before the intake
of the agent and after the last LDAEP recording. The
participants were given two further dosages of domperidone
10 mg for intake, if required, at noon and in the evening to
prevent nausea after the trial.
Data acquisition
Participants were seated upright in a comfortable chair with
their eyes open. They were instructed to relax throughout
the recording and to avoid facial muscle movement. Paying
attention to the auditory stimuli has been shown to
modulate the intensity of evoked potentials in humans
(Baribeau and Laurent 1987). In order to distract the
participants, a silent movie was shown during the presen-
tation of the auditory stimuli.
Electrophysiological measurements
EEG data were recorded using a BrainAmp amplifier and
the Brain Vision Recorder software (Brain Products GmbH,
Munich, Germany). Electrodes were applied to the scalp
using a carefully positioned nylon cap (BrainCap 32
standard with 32 channels (Easycap, Herrsching-
Breitbrunn, Germany)) in accordance with the International
10/20 System. Scalp electrode impedances were kept below
10 kΩ. The evoked responses were recorded with 32
electrodes referenced to Cz (32 channels). Sinus tones
(1,000 Hz, 40-ms duration with 10-ms rise and fall time, ISI
randomized between 1,800 and 2,400 ms) of 5 intensities
(60, 70, 80, 90, 100 dB sound pressure level, generated by
a PC-stimulator that was calibrated in the Department of
clinical audiology of the University of Zürich) were
presented binaurally via headphones in a pseudo-
randomized order using Presentation software (Neurobeha-
vioral Systems, Inc., San Pablo, CA). Data were collected
with a sampling rate of 1,000 Hz and a band pass filter of
0.5–80 Hz.
Event related potential processing
Periods of 100 ms pre stimulus and 300 ms post stimulus
time were evaluated for each of the five intensities with a
total of 350 sweeps. Before averaging, the first responses of
each of the five intensities were excluded in order to reduce
short-term habituation effects. For artifact suppression, all
trials were automatically excluded from averaging when the
voltage exceeded ±50 μV in any one of the 32 channels at
any point during the averaging period. For each participant,
the remaining sweeps were averaged separately for the five
intensity levels.
Dipole source analysis
A dipole source analysis (DSA) was computed with the
data of the resulting auditory evoked potentials N1 and P2
using the analysis and visualization software BESA®
(version 5.1.8, MEGIS, Gräfelfing, Germany). DSA pro-
vides a high spatio-temporal accuracy (Kawohl et al. 2007;
Waberski et al. 2003). A grand average over all subjects
was calculated. On the basis of this grand average a dipole
model was computed for the 60 and 70 dB intensities with
two regional sources (one for each hemisphere) (Fig. 1).
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Another dipole model was computed for the 80, 90
and 100 dB intensities and a third regional source was
added in the frontal region. A total of six equivalent
dipoles for each evoked potential was computed. The
tangential dipoles 1 and 3 represented the generators of
the evoked potentials localizing in the primary auditory
cortex. Dipoles 2 and 4 represent the generators in the
secondary auditory cortex. The source waveforms of
dipole 1 and 3 were used to compute the loudness
dependence. The methods have been published in detail
(Hegerl and Juckel 1993; Hegerl 1994; Hegerl et al.
1994; Hegerl and Juckel 1994). Additionally, N1 and P2
peaks were determined at the Cz electrode with an average
reference and re-referenced to linked mastoids (Fig. 2).
LDAEP processing
The LDAEP is the median of all slopes of each possible
connection between the five different N1/P2 amplitudes
corresponding to the five different intensities. The LDAEPs
of the tangential dipole activity as well the LDAEPs
computed of the Cz electrodes were used as the main
variables for statistical evaluation. A recent publication
underlines the need for processing both the data from single
electrode estimation and DSA (Hagenmuller et al. 2011).
The data were un-blinded after processing of the DSA and
the identification of the N1 and P2 peaks in the DSA- and
single-electrode data.
Statistical analysis
The data of one participant of the male levodopa group was
removed due to extreme values. The remaining variables were
analyzed for normal distribution with the Kolmogorov–
Smirnov test. Group differences (levodopa vs. placebo)
were assessed by unpaired t tests. Differences between
the two measurements within the groups were tested with
paired t tests.
Results
Kolmogorov–Smirnov test revealed a normal distribution
for LDAEP measurements at baseline for the single
electrode estimation data (mean 0.11 μV, SD 0.075 μV,
p .458) as well as the DSA data (left tangential source:
mean, 1.039 nA/m; SD, 0.767 nA/m; p .87; right tangential
source mean, 1.212 nA/m; SD, 0.949 nA/m; p .54).
After unblinding the data, it turned out that there were 11
females and nine males in the levodopa group and ten
females and 11 males in the placebo group.
No significant differences within the groups were found,
independently of the application of levodopa or placebo,
gender or the use of single electrode estimation or DSA
(Table 1; Figs. 3 and 4).
Fig. 1 Symmetrical dipole sources of auditory evoked potentials
following stimulationwith 70 dB localized in Brodmann area 41 (primary
auditory cortex, Talairach coordinates −38, −25, 11 and 38, −25, 11)
Fig. 2 Example of single subject auditory evoked potentials following
stimulation with different sound pressure levels (60 to 100 dB). Single
electrode data from Cz
Table 1 Within-group differences of N1/P2 slopes (expressed as
mean ± SD): paired t test (two-tailed) for within-group differences
(within the levodopa and placebo groups) between baseline and post
intervention measurement
Dipole ((nA/m)/10 dB) Cz (uV/10 dB)
Right Left
Levodopa group 0.074±1.07 0.098±0.58 0.008±0.34
Placebo group 0.009±0.36 0.004±0.56 0.005±0.04
Cz indicates data from single electrode estimation, dipole (e.g. left
dipole) means the tangential dipoles
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Irrespective of the estimation method or the time point of
the measurement (Table 2), no significant differences in the
LDAEP were found between the groups.
The test–retest reliability (Cronbachs Alpha) between
the baseline measurement and the intervention group
was 0.964 (levodopa) and 0.9 (placebo) for the Cz-
estimation and 0.911 (levodopa left tangential dipole),
0.67 (levodopa right tangential dipole), 0.759 (placebo
left tangential dipole) 0.923 (placebo right tangential
dipole).
Discussion
We had hypothesized that the acute synaptic dopamine
excess caused by levodopa intake is associated with an
intraindividual decrease of the LDAEP. In contrast to
this hypothesis, a difference between the baseline
measurement and the intervention was neither found in
the levodopa nor in the placebo group. Hence, a
synaptic dopaminergic excess caused by levodopa intake
did not lead to an acute LDAEP alteration. Furthermore,
the test–retest reliability between the baseline measure-
ment and the intervention group states a high correlation
between the two measurement conditions. Despite our
negative result, the high test–retest reliability between
the baseline and intervention group strengthens the
LDAEP as a reliable neurophysiologic parameter with
high individual stability.
We can only speculate about the cause for the
increase in variance of the left dipole source after
challenge with levodopa (Fig. 3). In the levodopa
intervention group, some volunteers presented with
nausea, which may have affected the data quality.
However, this does not explain the exclusive increase in
the left dipole. Another trial of our group (Wyss 2009)
shows similar findings; in patients with schizophrenia, a
larger variance in the amplitudes of left source waveforms
was found. The healthy control group, however, showed
no such increased variance. It is conceivable that a
dopaminergic influence on the LDAEP exists in single
subjects which only shows in a variance increase and not
in the mean of the data. Assuming such an individual
sensitivity exists, an examination of parameters influenc-
ing the LDAEP such as the COMT polymorphism would
be interesting. Our result stands in line with other findings
in the literature; O'Neill et al. (O'Neill et al. 2006, 2008b)
did not find any effect of acute dopamine receptor
stimulation with pergolide or bromocriptine on the
LDAEP. In the studies using dopamine receptor agonists
and in our trial an iatrogenic condition as a state factor is
used. So far studies suggesting a dopaminergic influence
on the LDAEP (Juckel et al. 2008b; Kawohl et al. 2008a;
Pogarell et al. 2004) show an association of the LDAEP
with trait factors, i.e. genetic variants in dopamine path-
ways. The LDAEP may rather present a chronic condition
dependent on genetic polymorphisms associated with the
5-HT/dopamine system (O'Neill et al. 2008a). In line with
this is a recent study by Lee (Lee et al. 2010) using
SPECT to approximate the availability of DATs and
SERTs. It provided further evidence for the possible
involvement of dopamine and serotonin in the genesis of
LDAEP. The correlation between monoamine transporter
availability and LDAEP could reflect the long-term
monoaminergic activity.
Fig. 4 Boxplot showing dipole source strengths [nA/m] of levodopa
and placebo group for the right dipole source (mad levodopa, pla
placebo, nat baseline measurement, int intervention, dsar dipole
source analysis right)
Fig. 3 Boxplot showing dipole source strengths [nA/m] of levodopa
and placebo group for the left dipole source (mad levodopa, pla
placebo, nat baseline measurement, int intervention, dsal dipole
source analysis left)
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Another recent study revealed an effect of a chronic
modulation of serotonergic neurotransmission on the
LDAEP (Simmons et al. 2011).
The LDAEP may therefore be considered to be a chronic
indicator of the 5-HT system and possibly the dopamine
system. Further studies are needed to determine if this also
applies for the dopamine system. This condition may be
robust against short-term changes in neurotransmission,
particularly dosages used in neuropsychopharmacology
(Norra et al. 2008; O'Neill et al. 2008a). Thus, it seems
questionable whether the LDAEP can actually be influ-
enced by short challenge trials in humans. Considering the
LDAEP as a chronic parameter, there is evidence support-
ing a positive relationship between personality traits such as
sensation seeking as well as impulsivity and the LDAEP;
higher scores on measures of sensation seeking have been
reported to be associated with an increased LDAEP and
possibly a lower 5-HT function (Brocke et al. 2000). Norra
et al. found a correlation between an increased LDAEP and
aspects of impulsiveness in patients with borderline
personality (Norra et al. 2003). Interestingly, dopaminergic
dysfunction seems to play an important role in borderline
personality disorder, affecting traits such as impulsivity.
Dopamine receptor polymorphism have been associated
with traits such as novelty seeking (Ebstein et al. 2000;
O'Neill et al. 2008a). In line with the aforementioned
supposition of the LDAEP acting as a chronic marker of
5-HT functioning is the finding of the individual LDAEP in
depressed patients not being altered after medical treatment
with a selective serotonin reuptake inhibitor (SSRI)
(Gallinat et al. 2000; Lee et al. 2005) after clinical
improvement of depressed symptoms. It has been shown
that general anxiety disorder (GAD) patients with a stronger
pretreatment LDAEP show a better response to a treatment
with the SSRI escitalopram (Park et al. 2011). Measurement
of the LDAEP was said to provide useful clinical
information for predicting treatment responses in patients
with GAD. Juckel et al. (Juckel et al. 2008a) postulate that
the LDAEP may be more closely related to genetic variants
controlling the 5-HT release (5-HT auto receptors) and
synthesis (tryptophan hydroxylase) rather than the
reuptake. In a study by the same study group, 5-HT1B
alleles were reported to be associated with an increased
LDAEP (Juckel et al. 2008a). The 5-HT1B receptor is
located presynaptically on serotonergic axon terminals. It
occurs in high densities in the primary auditory cortex and
in the brainstem raphe nuclei (Moret and Briley 2000). In
addition to controlling 5-HT release in terminal areas, this
receptor inhibits the release and synthesis of 5-HT and
reduces the firing rate of serotonergic neurons via a
negative feedback loop in the raphe nuclei (Moret and
Briley 2000). Interestingly, 5-HT1B receptors can also
function as a heteroreceptor at non-serotonergic neurons
controlling the release of neurotransmitters other than
5-HT (such as dopamine, acetylcholine and glutamate)
(Moret and Briley 2000). Thus, the 5-HT and dopamine
interactions and their possibly influence on the LDAEP
may be complex.
Our study is not without limitations. Ideally, blood
samples should have been taken to estimate the
individual levodopa blood levels at its estimated tmax
of 60 min after oral intake. Due to practical reasons, we
refrained from conducting a crossover study. Nevertheless,
we do not expect any additional outcome by such a
design. Other limitations regarding the statistical power
are the rather small sample size and low dosage of
levodopa. Possibly a higher dosage of levodopa or a
bigger sample size could have shown different results.
Nevertheless, based upon our data, a number of 3,124
persons per group would be needed (power 0.9) in order to
show significance within group differences given these
results. This is clearly not practicable. On the other hand,
our sample size would have been large enough to detect a
moderate effect of 0.5 with a power of 48.2% or a larger
effect of 0.8 with a power of 82% (Cohen 1992).
Additionally, other dopaminergic influences associated
with the LDAEP like the COMT polymorphism could
have been examined.
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Table 2 Between-group differences (expressed as mean: mean difference, standard: standard error difference); unpaired t test (two-tailed) for
differences between the placebo and the levodopa group (baseline and intervention)
Dipole Cz
Right Left
Mean Standard Mean Standard Mean Standard
Baseline Equal variances −0.19 0.30 0.05 0.24 −0.03 0.02
Unequal variances −0.20 0.30 0.05 0.24 −0.03 0.02
Intervention Equal variances −0.12 0.30 −0.01 0.30 −0.04 0.03
Unequal variances −0.12 0.30 −0.01 0.30 −0.04 0.03
Cz indicates data from single electrode estimation, dipole (e.g. left dipole) means the tangential dipoles
Conclusion
Our study shows an absence of acute dopaminergic
influence due to a single intake of levodopa on the LDAEP.
Our findings are in agreement with the findings of O`Neill
et al. (O'Neill et al. 2006, 2008b) stating the absence of
acute dopaminergic influence on the LDAEP. To our
knowledge, our study is the first trial having computed
the data via dipole source analysis and Cz estimation.
As dopamine possibly may be a chronic parameter
concerning the LDAEP, studies with, e.g. longer dopamine
intake in healthy volunteers may be needed to examine a
dopaminergic influence on the LDAEP.
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